Abstract
Pharmacological properties of the human P2Y1 receptor transfected in Jurkat cells and of the endogenous receptor in rat brain capillary endothelial cells were analyzed under conditions in which the purity of adenine triphosphate nucleotides was controlled by creatine phosphate/creatine phosphokinase (CP/CPK). ATP, a partial agonist of the receptor, was inactive in the presence of CP/CPK. Results further indicated that ATP was a competitive antagonist of ADP actions.K i values were 23.0 ± 1.5 μm in endothelial cells and 14.3 ± 0.3 μm in Jurkat cells. Solutions prepared from commercially available 2-methylthio-ATP (2-MeSATP) or 2-chloro-ATP (2-ClATP) contained ≈10% of ADP derivatives. ADP derivatives were removed from the solution by treatment with CP/CPK. Purified 2-MeSATP and 2-ClATP antagonized platelet aggregation induced by ADP. They did not activate P2Y1 receptors but prevented ADP actions in a competitive manner. K i values for 2-MeSATP were 36.5 μm in endothelial cells and 5.7 ± 0.4 μm in Jurkat cells, andK i values for 2-ClATP were 27.5 μm in endothelial cells and 2.3 ± 0.3 μm in Jurkat cells. EDTA potentiated actions of ADP and ATP on endothelial cells by 2.4- and 3.6-fold, respectively. In conclusion, the rat and human P2Y1 receptors are ADP-specific receptors that recognize ADP and 2-methylthio-ADP, whereas ATP, 2-MeSATP, and 2-ClATP are competitive antagonists. The results further point to the close pharmacological similarity of the P2Y1 receptor and the platelet ADP receptor.
Footnotes
- Received September 30, 1997.
- Accepted December 29, 1997.
-
Send reprint requests to: Dr. Christian Frelin, Institut de Pharmacologie Moléculaire et Cellulaire, CNRS UPR 411, 660 route des Lucioles, 06560 Valbonne, France, E-mail:frelin{at}ipmc.cnrs.fr or Dr. Christian Gachet, INSERM U311, ETSS, 10 rue Spielmann, BP 36, 67065 Strasbourg Cédex, France, E-mail:christian.gachet{at}etss.u-strasbg.fr
-
This work was supported by the Centre Nationale de Recherche Scientifique and by Institut National de la Santé et de la Recherche Médicale.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|